Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 2:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 229 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Moderate Alzheimer Disease Clear all
Completed Phase 2 Interventional

Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease

NCT00257673
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
MEM 1003, Placebo for MEM 1003
Drug
Lead sponsor
Memory Pharmaceuticals
Industry
Eligibility
50 Years to 90 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
57
States / cities
Northport, Alabama • Mesa, Arizona • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated May 6, 2008 · Synced Oct 3, 2026, 2:09 PM EDT
Completed Phase 2 Interventional

Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)

NCT00104273
View directory record Official record
Conditions
Dementia, Alzheimer's Disease
Interventions
Rasagiline
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
45 Years to 90 Years
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
31
States / cities
Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2009 · Synced Oct 3, 2026, 2:09 PM EDT
Completed Phase 3 Interventional

The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease

NCT00090116
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Neramexane
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
50 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
34
States / cities
Peoria, Arizona • Phoenix, Arizona • Fresno, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Oct 3, 2026, 2:09 PM EDT
Withdrawn Phase 1 Interventional

A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease

NCT03316898
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AGN-242071, Placebo, Donepezil, Memantine
Drug
Lead sponsor
Allergan
Industry
Eligibility
55 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
6
States / cities
Costa Mesa, California • Irvine, California • Lemon Grove, California + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2018 · Synced Oct 3, 2026, 2:09 PM EDT
Completed Phase 2 Interventional

A Study of RO5313534 as Add-on to Donepezil Treatment in Patients With Mild to Moderate Alzheimer's Disease

NCT00884507
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, RO5313534
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
15
States / cities
Orange, California • Torrance, California • Norwalk, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 3, 2026, 2:09 PM EDT
Completed Phase 2 Interventional Results available

Study of BHV-4157 in Alzheimer's Disease

NCT03605667
View directory record Official record
Conditions
Alzheimer Disease
Interventions
troriluzole, Placebo oral capsule
Drug
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
44
States / cities
Phoenix, Arizona • Sun City, Arizona • Fullerton, California + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Oct 3, 2026, 2:09 PM EDT
Completed Phase 2 Interventional

SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD)

NCT00093951
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
SGS742
Drug
Lead sponsor
Saegis Pharmaceuticals
Industry
Eligibility
55 Years to 90 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
59
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2009 · Synced Oct 3, 2026, 2:09 PM EDT
Suspended Phase 3 Interventional

A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease

NCT04520412
View directory record Official record
Conditions
Alzheimer Disease
Interventions
GV-971, Placebo
Drug
Lead sponsor
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Industry
Eligibility
50 Years to 85 Years
Enrollment
2,046 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
67
States / cities
Gilbert, Arizona • Phoenix, Arizona • Sun City, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2022 · Synced Oct 3, 2026, 2:09 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease

NCT01561053
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Albumin 5%, Albumin 20%, Immunoglobulin
Biological
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
55 Years to 85 Years
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
22
States / cities
Sacramento, California • Denver, Colorado • Washington D.C., District of Columbia + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 3, 2026, 2:09 PM EDT
Completed Phase 3 Interventional

18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type

NCT00103649
View directory record Official record
Conditions
Alzheimer Disease
Interventions
xaliproden (SR57746A)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
1,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
97
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2008 · Synced Oct 3, 2026, 2:09 PM EDT
Completed Phase 3 Interventional

Study of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type

NCT00104013
View directory record Official record
Conditions
Alzheimer Disease
Interventions
xaliproden (SR57746A)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
1,455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
32
States / cities
Mesa, Arizona • Peoria, Arizona • Tucson, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2008 · Synced Oct 3, 2026, 2:09 PM EDT
Terminated Phase 3 Interventional Results available

Open-label Extension for Phase 3 Clinical Trials of Simufilam

NCT05575076
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Simufilam
Drug
Lead sponsor
Cassava Sciences, Inc.
Industry
Eligibility
51 Years to 89 Years
Enrollment
1,081 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
107
States / cities
Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 94 more
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 3, 2026, 2:09 PM EDT
Completed Phase 2 Interventional

A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease

NCT00566397
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PF-04494700, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
62
States / cities
Phoenix, Arizona • Sun City, Arizona • Irvine, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2018 · Synced Oct 3, 2026, 2:09 PM EDT
Completed Phase 2 Interventional

Study Evaluating Lecozotan SR in Mild to Moderate Alzheimer's Disease (AD)

NCT00151398
View directory record Official record
Conditions
Alzheimer Disease
Interventions
lecozotan SR, Donepezil
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
50 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
35
States / cities
Phoenix, Arizona • Tucson, Arizona • Costa Mesa, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 6, 2022 · Synced Oct 3, 2026, 2:09 PM EDT
Terminated Phase 2 Interventional

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

NCT01676935
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ABT-126
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
55 Years to 90 Years
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
Delray Beach, Florida • West Palm Beach, Florida • Elk Grove Village, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 3, 2026, 2:09 PM EDT
Completed Phase 3 Interventional Results available

Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil

NCT01955161
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, Idalopirdine
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
50 Years and older
Enrollment
933 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
46
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced Oct 3, 2026, 2:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of RO7105705 in Healthy Participants and Participants With Mild-to-Moderate Alzheimer's Disease

NCT02820896
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, RO7105705
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 3, 2026, 2:09 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Care Planning for a Loved One With Dementia: Knowledge, Preparing for Decisions, and Emotions

NCT05165186
View directory record Official record
Conditions
Dementia, Dementia Frontotemporal, Dementia Alzheimers, Dementia, Mild, Dementia Moderate, Dementia Severe, Caregiver Burnout, Caregiver Stress Syndrome
Interventions
Video Intervention Arm
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 19, 2023 · Synced Oct 3, 2026, 2:09 PM EDT
Completed Phase 1 Interventional

Anti-Oxidant Treatment of Alzheimer's Disease

NCT00117403
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Vitamin E, Vitamin C, and Alpha-lipoic Acid, Coenzyme Q, Placebo capsules, Placebo wafers
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
60 Years to 85 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
13
States / cities
Tucson, Arizona • Irvine, California • La Jolla, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2009 · Synced Oct 3, 2026, 2:09 PM EDT
Completed Phase 1 Interventional

Single Dose Escalation Study of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease

NCT00733642
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PF-04360365 1 mg/kg, PF-04360365 3 mg/kg, PF-04360365 5 mg/kg, PF-04360365 10 mg/kg
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Glendale, California • Eatontown, New Jersey • Oakhurst, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 28, 2009 · Synced Oct 3, 2026, 2:09 PM EDT
Completed Phase 2 Interventional Results available

Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease

NCT02947893
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo Capsule(s) Once a Day by Mouth, Nilotinib Capsule(s) Once a Day by Mouth
Drug
Lead sponsor
Georgetown University
Other
Eligibility
50 Years to 85 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 3, 2026, 2:09 PM EDT
Completed Phase 1 Interventional Results available

A Brief Study To Evaluate The Safety, Tolerability, And Blood Levels Of Multiple Doses Of PF-044467943 Or Placebo In Combination With Donepezil In Subjects With Mild To Moderate Alzheimer's Disease

NCT00988598
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PF-04447943, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
55 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Glendale, California • Gainesville, Florida • Hallandale, Florida
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Oct 3, 2026, 2:09 PM EDT
Completed Phase 2 Interventional Results available

Rasagiline Rescue in Alzheimer's Disease Clinical Trial

NCT02359552
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rasagiline, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
50 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
3
States / cities
Las Vegas, Nevada • Cleveland, Ohio • Lakewood, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 10, 2020 · Synced Oct 3, 2026, 2:09 PM EDT
Suspended Not applicable Interventional

Neuro RX Gamma - Pivotal Phase

NCT03484143
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Active Neuro RX Gamma device, Sham Neuro RX Gamma device
Device
Lead sponsor
Vielight Inc.
Industry
Eligibility
50 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Oct 3, 2026, 2:09 PM EDT